Ola Sandborgh takes office as CEO for Lipum AB today
Lipum AB (publ) is strengthening its leadership when going into phase II by appointing Ola Sandborgh as its new CEO where he takes over the helm from Einar Pontén.
Ola has more than three decades of experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and business development positions in companies such as Pfizer, Sanofi Pasteur MSD and, most recently, as Vice President Immunology & Specialty Care at Swedish Orphan Biovitrum (Sobi). Ola has been leading global cross functional teams as well as coordinating partnerships with numerous of companies, contributing in several early to late-stage development projects and acquiring a significant experience within M&A ́s and DD ́s.
Einar Pontén, who has successfully transformed Lipum into a publicly listed clinical stage company will take a business development role to facilitate a smooth transfer of responsibilities and to support further activities.
“Lipum is a unique company and a very interesting innovative player in the anti-inflammatory field. With a strong scientific background revealing that the novel target molecule BSSL plays an important role in inflammation, Lipum is on an exciting journey. I am delighted to be appointed as CEO and look forward to being leading the team on this path of strong innovation and development to the benefit for patients with inflammatory disorders, which also will create value for the shareholders of Lipum,” says Ola Sandborgh
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company’s share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.